Enrollment completed for phase 3 trial of new gonorrhea antibiotic
24 May 2023
24 May 2023
The Global Antibiotic Research & Development Partnership (GARDP) and Innoviva Specialty Therapeutics announced yesterday that they have completed enrollment for a phase 3 trial of an investigational antibiotic for uncomplicated gonorrhea infections.
The trial is evaluating the efficacy of oral zoliflodacin against Neisseria gonorrhoeae infections in comparison with the standard regimen of ceftriaxone plus azithromycin. A total of 958 patients have been recruited from 16 sites in five countries (Belgium, the Netherlands, South Africa, Thailand, and the United States) since November 2019. GARDP says it’s the largest clinical trial ever for a new gonorrhea treatment.